Regional antineoplastic drug delivery is not a new concept. Following the initial recognition that cytotoxic alkylating agents could cause shrinkage of tumor masses and a reduction in the quantity of malignant ascites in patients with advanced ovarian cancer, investigators in the 1950s instilled the drugs directly into the peritoneal cavity in an effort to treat the malignancy (1). Similarly, i...

OBJECTIVES Antineoplastic drugs are known reproductive and developmental toxicants. Our objective was to review the existing literature of reproductive health risks to workers who handle antineoplastic drugs. METHODS A structured literature review of 18 peer-reviewed, English language publications of occupational exposure and reproductive outcomes was performed. RESULTS Although effect size...

Six murine tumors, including ascetic tumors HepA, EC, P388 leukemia, S180 and solid tumor S180, and Lewis lung carcinoma, were employed in this work. The free sialic acid concentrations in both blood and ascites were measured in tumor-bearing mice. The results showed that the content of sialic acids in blood was increased in tumor growth and certain tumor types. Higher sialic acid content was o...

Cytostatic antineoplastic drugs are considered carcinogenic and mutagenic risk factors for health workers who are occupationally exposed to them; however, the molecular mechanisms underlying these effects remain to be elucidated. Therefore, the present study aimed to investigate the underlying mechanisms of antineoplastic drugs‑induced apoptosis of peripheral blood lymphocytes (PBLs) obtained f...

A global, comprehensive and open access listing of approved anticancer drugs does not currently exist. Partial information is available from multiple sources, including regulatory authorities, national formularies scientific agencies. Many such data sources include used in oncology for supportive care, diagnostic or other non-antineoplastic uses. We describe a methodology to combine cleanse rel...